Teva Launches Exclusive First-to-File Generic Version of Cialis in the US

 Teva Launches Exclusive First-to-File Generic Version of Cialis in the US

Teva Launches Exclusive First-to-File Generic Version of Cialis in the US

Shots:

  • Teva launches generic version of Cialis (tadalafil) tablets with dosage (2.5 mg, 5 mg, 10 mg, 20 mg) in the US, with 180 days ANDA exclusivity before the FDA approves other generics
  • Cialis tablets are a phosphodiesterase 5 (PDE5) inhibitor used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and with finasteride to initiate BPH treatment for 26 weeks
  • On an average 30M men are affected with ED and 15M have symptomatic BPH in the US. In July, 2018 Lily’s Cialis had an annual sales of ~ $1.9B in the US

Click here to read full press releasearticle | Ref: Teva pharmaceuticals | Image: Investinontario

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post